interleukin 23 receptor
Last updated 17 Jul 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The IL23R gene provides instructions for making a protein called the interleukin 23 (IL-23) receptor. This protein is embedded in the outer membrane of several types of immune system cells, including T cells, natural killer (NK) cells, monocytes, and dendritic cells. These cells identify foreign substances and defend the body against infection and disease.
Video picks for GenesVideo library
Normal function
The IL23R gene provides instructions for making a protein called the interleukin 23 (IL-23) receptor. This protein is embedded in the outer membrane of several types of immune system cells, including T cells, natural killer (NK) cells, monocytes, and dendritic cells. These cells identify foreign substances and defend the body against infection and disease.
At the cell surface, the IL-23 receptor interacts with a protein called IL-23. These two proteins fit together like a lock and key. IL-23 is a cytokine, which is a type of protein that regulates the activity of immune cells. When IL-23 binds to its receptor, it triggers a series of chemical signals inside the cell. These signals promote inflammation and help coordinate the immune system's response to foreign invaders such as bacteria and viruses.
Conditions referring to this gene or chromosome
Other names
IL-23R
IL23R_HUMAN
interleukin-23 receptor
Patient picks for Genes

Medicine
Pneumococcal vaccines for adults and children
Pneumococcal vaccines help to protect against infections such as pneumonia and meningitis. The vaccine will be injected into a muscle or under the surface of your skin. The most common side-effects are tenderness at the site of the injection, a raised temperature (mild fever), feeling tired, and head/muscle aches. These should soon pass.
by Michael Stewart, MRPharmS

Medicine
Valsartan - an angiotensin receptor blocker
You can take valsartan either before or after a meal. Any side-effects are usually mild. The most common side-effect is dizziness. Some painkillers may interfere with valsartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Irbesartan - an angiotensin receptor blocker
Take irbesartan once each day. You can take the tablets before or after meals. Side-effects are usually mild. They include feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with irbesartan, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Candesartan - an angiotensin receptor blocker
Take candesartan once each day. You can take the tablets either before or after a meal. Any side-effects are usually mild. They include headache and feeling dizzy. Some painkillers may interfere with candesartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Telmisartan - an angiotensin receptor blocker
The usual dose is one tablet daily. You can take telmisartan before or after meals. Side-effects are usually mild. They include feeling dizzy and stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with telmisartan, so ask your pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Eprosartan - an angiotensin receptor blocker
The usual dose is one 600 mg tablet daily. Side-effects are usually mild. They include headache, feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with eprosartan. Ask your pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS
Related patient information and medicines

Patient information leaflet
Mouth cancer
Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. Immun... It is also sometimes called biological therapy: Recombinant interleukin (rIL-2) is.

Patient information leaflet
Mastocytosis and mast cell disorders
Triggers for mastocytosis symptoms Although not strictly speaking the cause of mastocytosis, a number of factors. If the condition is severe, surgery to remove the spleen... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.

Patient information leaflet
Myasthenia gravis
Myasthenia gravis (MG) is a condition where muscles become easily tired and weak. It is due to a problem with how the nerves stimulate the muscles to tighten (contract). The muscles around the eyes are commonly affected first. What causes myasthenia gravis. Myasthenia gravis is an autoimmune disease. This means that the immune system The immune.

Patient information leaflet
Can I take Bisoprolol and Trimbow together?
Bisoprolol and Trimbow (which contains formoterol) work in opposite ways on the airways. It also makes the formoterol in the Trimbow inhaler less effective at opening your airways. Why this happens Bisoprolol is a 'beta-blocker' and formoterol (in Trimbow) is a 'beta-agonist'. They compete for the same receptors in the lungs. Always consult your.

Patient information leaflet
Planning to become pregnant
This is ideally done before pregnancy. There is a summary checklist at the end of the leaflet. Women who are already pregnant may find Diet and lifestyle during pregnancy Diet and lifestyle during pregnancy more help. When should I have my next baby. Studies have shown that having very long or very short gaps between pregnancies can result in.

Patient information leaflet
Diabetic kidney disease
Diabetic kidney disease is a complication that occurs in some people with diabetes. It can progress to kidney failure in some cases. Treatment aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases such as heart attack and stroke which are much more common than average in.
Further reading and references
- interleukin 23 receptor; MedlinePlus, National Library of Medicine.
- Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, Samadi M, Rafatpanah H. Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review. J Immunotoxicol. 2016 May;13(3):286-300. doi: 10.3109/1547691X.2015.1115448. Epub 2016 Apr 4.
- Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007 Sep;122(2):201-6. doi: 10.1007/s00439-007-0397-0. Epub 2007 Jun 22.
- Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006 Dec 1;314(5804):1461-3. doi: 10.1126/science.1135245. Epub 2006 Oct 26.
- Kannan AK, Su Z, Gauvin DM, Paulsboe SE, Duggan R, Lasko LM, Honore P, Kort ME, McGaraughty SP, Scott VE, Gauld SB. IL-23 induces regulatory T cell plasticity with implications for inflammatory skin diseases. Sci Rep. 2019 Nov 27;9(1):17675. doi: 10.1038/s41598-019-53240-z.
- Nancy Z, Yan L, Hui S, Paul B, Liye C. From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery. Front Immunol. 2021 Feb 17;12:624632. doi: 10.3389/fimmu.2021.624632. eCollection 2021.
- Rueda B, Orozco G, Raya E, Fernandez-Sueiro JL, Mulero J, Blanco FJ, Vilches C, Gonzalez-Gay MA, Martin J. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2008 Oct;67(10):1451-4. doi: 10.1136/ard.2007.080283. Epub 2008 Jan 16.
- Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, Gorman DM, Bowman EP, McClanahan TK, Yearley JH, Eberl G, Buckley CD, Kastelein RA, Pierce RH, Laface DM, Cua DJ. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012 Jul 1;18(7):1069-76. doi: 10.1038/nm.2817.
- Sherlock JP, Taylor PC, Buckley CD, Cua DJ. Spondyloarthropathy: interleukin 23 and disease modification. Lancet. 2015 May 23;385(9982):2017-8. doi: 10.1016/S0140-6736(15)60970-9. No abstract available.
- Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, Kastelein R, Nickoloff BJ, Nestle FO. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010 Nov 15;185(10):5688-91. doi: 10.4049/jimmunol.1001538. Epub 2010 Oct 18.
- Wang MH, Picco MF. Crohn's Disease: Genetics Update. Gastroenterol Clin North Am. 2017 Sep;46(3):449-461. doi: 10.1016/j.gtc.2017.05.002. Epub 2017 Jul 19.
- Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC); Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, McCarthy MI, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Barrett JC, Davison D, Easton D, Evans DM, Leung HT, Marchini JL, Morris AP, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamshere ML, Holmans PA, Jones IR, Kirov G, Moskivina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop TD, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Matthew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop MG, Connell J, Dominiczak A, Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A; Biologics in RA Genetics and Genomics Study Syndicate (BRAGGS) Steering Committee; Bruce IN, Donovan H, Eyre S, Gilbert PD, Hilder SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Frayling TM, Freathy RM, Lango H, Perry JR, Shields BM, Weedon MN, Hattersley AT, Hitman GA, Walker M, Elliott KS, Groves CJ, Lindgren CM, Rayner NW, Timpson NJ, Zeggini E, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S; Breast Cancer Susceptibility Collaboration (UK); Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Newport M, Sirugo G, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghori MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widden C, Withers D, Cardin NJ, Davison D, Ferreira T, Pereira-Gale J, Hallgrimsdo'ttir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Brown MA, Compston A, Farrall M, Hall AS, Hattersley AT, Hill AV, Parkes M, Pembrey M, Stratton MR, Mitchell SL, Newby PR, Brand OJ, Carr-Smith J, Pearce SH, McGinnis R, Keniry A, Deloukas P, Reveille JD, Zhou X, Sims AM, Dowling A, Taylor J, Doan T, Davis JC, Savage L, Ward MM, Learch TL, Weisman MH, Brown M. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007 Nov;39(11):1329-37. doi: 10.1038/ng.2007.17. Epub 2007 Oct 21.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

